Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness

• Published in: International journal of chronic obstructive pulmonary disease Vol. 16; pp. 41 - 51
• Main Authors: Horne, Benjamin D, Ali, Rehan, Midwinter, Dawn, Scott-Wilson, Catherine, Crim, Courtney, Miller, Bruce E, Rubin, David B
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2021; Dove Medical Press Ltd; Dove; Dove Medical Press
• Subjects: Analysis; arterial stiffness; Blood tests; cardiovascular (cv) risk; Cardiovascular disease; Chronic obstructive pulmonary disease; chronic obstructive pulmonary disease (copd); Double-Blind Method; Dyspnea; Fluticasone; Heart attacks; Heart failure; Humans; intermountain risk score (imrs); Laboratories; Lung diseases; Medical research; Medicine, Experimental; Metabolism; Mortality; Original Research; Pharmaceutical industry; Pneumonia; Pulmonary Disease, Chronic Obstructive - diagnosis; Pulmonary Disease, Chronic Obstructive - drug therapy; Pulmonary Disease, Chronic Obstructive - epidemiology; Pulse Wave Analysis; Retrospective Studies; risk assessment; Risk factors; Spirometry; summit lab score; Vascular Stiffness; United Kingdom; United Kingdom > UK; United States > US; California; arterial stiffness; risk assessment; Intermountain Risk Score (IMRS); cardiovascular (CV) risk; Summit Lab Score; chronic obstructive pulmonary disease (COPD)
• ISSN: 1178-2005; 1176-9106; 1178-2005
• DOI: 10.2147/COPD.S279645

The presence of cardiovascular (CV) risk factors and CV disease in patients with chronic obstructive pulmonary disease (COPD) leads to worse outcomes. A number of tools are currently available to stratify the risk of adverse outcomes in these patients with COPD. This post hoc analysis evaluated the Summit Lab Score for validation as a predictor of the first episode of moderate-to-severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and other outcomes, in patients with COPD and high arterial pulse wave velocity (aPWV). Data from a multicenter, randomized, placebo-controlled, double-blind study were retrospectively analyzed to evaluate treatment effects of once-daily fluticasone furoate/vilanterol 100/25 μg in patients with COPD and an elevated CV risk (aPWV≥11m/s) over 24 weeks. The previously derived Summit Lab Score and, secondarily, the Intermountain Risk Score (IMRS) were computed for each patient, with patients then stratified into tertiles for each score. Risk of moderate-to-severe AECOPD was analyzed across tertiles using Kaplan-Meier survival curve and Cox regression analyses. In 430 patients with COPD, Kaplan-Meier probabilities of no moderate-to-severe AECOPD for Summit Lab Score tertiles 1, 2, and 3 were 92.3%, 95.5%, and 85.1%, respectively ( trend = 0.015), over 24 weeks. Grouped by IMRS tertiles, the respective probabilities were 92.9%, 91.2%, and 88.3%, respectively ( trend = 0.141). Length of stay in the hospital ( = 0.034) and the hospital ward ( = 0.042) were also significantly different between Summit Lab Score tertiles but not for intensive care ( = 0.191). The Summit Lab Score was associated with the 24-week risk of moderate-to-severe AECOPD in COPD patients with elevated CV risk. Secondarily, IMRS showed a trend towards differences in the risk of AECOPD, which was not statistically significant.